Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transgender men are individuals born genetically female that have a gender identity that is incongruent with their biological sex. For those who have begun or completed transition, they may present as males but still have a uterus and cervix. Thus far, no distinction has been made between routine cervical cancer screening guidelines in non-transgender women and those for transgender men, despite wide variations in sexual practices, including lifelong vaginal abstinence. The purpose of this study is to offer transgender men seen at clinic visits self-collected HPV testing to evaluate for improved cervical cancer screening rates, as well as a survey to further investigate sexual practices, rates of appropriate screening prior to being offered self-collection, and barriers to obtaining appropriate care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals

NCT03222817

Cervical Cancer Screening

COMPLETED NA

HPV Self-testing in Transgender Individuals

NCT05883111

HPV Infection

RECRUITING NA

Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy

NCT07075731

Cancer Screening Transgender Gender Diverse Populations

RECRUITING

Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests

NCT05536843

Cervical Dysplasia, Uterine Vaginal Dysplasia Vulvar Dysplasia

UNKNOWN

HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population

NCT05981807

Human Papillomavirus Infection Human Immunodeficiency Virus Infection Sexually Transmitted Diseases

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transgenderism Cervical Cancer Human Papilloma Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HPV Testing

Will perform HPV testing with self-collected specimen

Group Type EXPERIMENTAL

HPV testing

Intervention Type DIAGNOSTIC_TEST

will perform HPV testing with self-collected specimen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HPV testing

will perform HPV testing with self-collected specimen

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>21 for survey and age\> 25 for HPV testing
* Transgender male or gender non-conforming identity
* Female sex at birth
* Consent to participate in the study